Review anchor
Inhibitor of nuclear factor kappa-B kinase subunit epsilon
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Inhibitor of nuclear factor kappa-B kinase subunit epsilon
CHEMBL3529
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Inhibitor of nuclear factor kappa-B kinase subunit epsilon as ChEMBL target CHEMBL3529, mapped to UniProt Q14164. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3529
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q14164
Inhibitor of nuclear factor kappa-B kinase subunit epsilon
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Inhibitor of nuclear factor kappa-B kinase subunit epsilon matters
Inhibitor of nuclear factor kappa-B kinase subunit epsilon is reviewed as Inhibitor of nuclear factor kappa-B kinase subunit epsilon (UniProt Q14164); the current evidence base includes 12 approved drugs, 2174 compounds, and 349 assays, with lead potency reaching pChEMBL 9.7.
Protein context
Inhibitor of nuclear factor kappa-B kinase subunit epsilon
Inhibitor of nuclear factor kappa-B kinase subunit epsilon Sequence length is 716 aa.
Review this target as Inhibitor of nuclear factor kappa-B kinase subunit epsilon, mapped to UniProt Q14164. Sequence length is 716 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q14164
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 12 approved drugs, 2174 compounds, and 349 assays for this target. The dominant activity type is IC50. CHEMBL388978 is the current potency anchor at pChEMBL 9.7.
Use CHEMBL388978 as the tractability anchor when discussing potency (pChEMBL 9.7).
Activity source · ChEMBL 36 via Core Engine
12 approved
pChEMBL 9.7
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Inhibitor of nuclear factor kappa-B kinase subunit epsilon matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q14164, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
2174
Total Compounds
349
Total Assays
12
Approved Drugs
IC50: 861.0, KI: 329.0, KD: 368.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL388978
|
9.7 | IC50 | — |
|
|
No preferred name
CHEMBL3682430
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL3687186
|
8.7 | IC50 | — |
|
|
No preferred name
CHEMBL4537673
|
8.7 | IC50 | — |
|
|
No preferred name
CHEMBL4566796
|
8.7 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
MOMELOTINIB
CHEMBL1078178
|
2023 |
|
|
PACRITINIB
CHEMBL2035187
|
2022 |
|
|
FEDRATINIB
CHEMBL1287853
|
2019 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
NINTEDANIB
CHEMBL502835
|
2014 |
|
|
BOSUTINIB
CHEMBL288441
|
2012 |
|
|
CRIZOTINIB
CHEMBL601719
|
2011 |
|
|
SUNITINIB
CHEMBL535
|
2006 |
Source Header